AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10643677 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (12 months)
Number of subjects: 27
Study 10643677 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-trained group
Number of subjects: 27
Study 9025128 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression cardiopulmonary resuscitation (ACD-CPR)
Number of subjects: 220
Study 9025128 — intervention group
Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 220
Study 2060563 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 0.5 mg
Number of subjects: 45
Study 2060563 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg
Number of subjects: 45
Study 2060563 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 6637861 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 2
Study 6637861 — intervention group
Group type: COMPARATOR
Intervention: Treatment group 2
Number of subjects: 2
Study 30648524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) 1500 mg + 1200 mg daily for 6 months
Number of subjects: 189
Study 30648524 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 6 months
Number of subjects: 189
Study 30576794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab treatment with NSAIDs <90 days (limited NSAID users)
Number of subjects: 139
Study 30576794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab treatment with NSAIDs ≥90 days (chronic NSAID users)
Number of subjects: 139
Study 30576794 — intervention group
Group type: COMPARATOR
Intervention: Control group (OA patients without the biomarker phenotype)
Number of subjects: 139
Study 28871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 40
Study 28871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET)
Number of subjects: 40
Study 28871849 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training plus Diet (RT+DIET)
Number of subjects: 40
Study 28871849 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study 27630954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% povidone iodine
Number of subjects: 30
Study 27630954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30
Study 27630954 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study 25124577 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlux/DL device
Number of subjects: 599
Study 25124577 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlux/DL device with toluidine blue
Number of subjects: 599
Study 25124577 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oral Examination (COE)
Number of subjects: 599
Study 22250063 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate (27 g/day, containing 850 mg flavan-3-ols and 100 mg isoflavones)
Number of subjects: 93
Study 22250063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 18805590 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 175
Study 17625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetins (specific types not mentioned)
Number of subjects: 0
Study 17625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional data analysis
Number of subjects: 0
Study 17625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase plotting analysis
Number of subjects: 0
Study 17625113 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification of notional instability of patient responses
Number of subjects: 0
Study 15805374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco intervention (30-second clinician advice, 10-minute interactive computer program, 5-minute motivational interview, up to two 10-minute booster sessions)
Number of subjects: 2526
Study 15805374 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (5-minute motivational intervention to promote increased consumption of fruits and vegetables)
Number of subjects: 2526
Study 15805374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco intervention
Number of subjects: 2526
Study 10212711 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (parturient-controlled epidural analgesia) - bolus 5 ml, lockout 15 minutes
Number of subjects: 40
Study 10212711 — intervention group
Group type: COMPARATOR
Intervention: CIEA (continuous infusion epidural analgesia) - 8 ml/h
Number of subjects: 40
Study 7832129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator, anistreplase, or both (exact dosage and duration not specified)
Number of subjects: 382
Study 2078983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (single dose)
Number of subjects: 0
Study 2078983 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (single dose)
Number of subjects: 0
Study 2078983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 532796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 5
Study 532796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin
Number of subjects: 5
Study 532796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR ≤60 mL/min/1.73 m2
Number of subjects: 19391
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR = 45 mL/min/1.73 m2
Number of subjects: 19391
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <75 mL/min/1.73 m2
Number of subjects: 19391
Study 31951261 — intervention group
Group type: COMPARATOR
Intervention: eGFR ≥75 mL/min/1.73 m2
Number of subjects: 19391
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals (45 years)
Number of subjects: 19391
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals (65 years)
Number of subjects: 19391
Study 31951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 19391
Study 30663038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (30-70 l.min-1)
Number of subjects: 40
Study 30663038 — intervention group
Group type: COMPARATOR
Intervention: Standard flow-rate facemask (15 l.min-1)
Number of subjects: 40
Study 27914309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training with a new device (5-6 weeks)
Number of subjects: 72
Study 27914309 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective assessment of balance
Number of subjects: 72
Study 23910386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite-coated mini-implants
Number of subjects: 25
Study 23910386 — intervention group
Group type: COMPARATOR
Intervention: Commercially pure titanium mini-implants
Number of subjects: 25
Study 23910386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implant surfaces (nano-hydroxyapatite-coated and cp titanium)
Number of subjects: 25
Study 23362969 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg early induction regimen (weeks 0, 1, 2, 4)
Number of subjects: 404
Study 23362969 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg monthly induction regimen (weeks 0, 4, 8)
Number of subjects: 404
Study 23362969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 23362969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-interval secukinumab (150 mg at weeks 12 and 24)
Number of subjects: 404
Study 23362969 — intervention group
Group type: EXPERIMENTAL
Intervention: Start-of-relapse secukinumab (150 mg at visits at which a start of relapse was observed)
Number of subjects: 404
Study 21143704 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (starting dose 300 mg once daily to a target of 900 mg daily)
Number of subjects: 140
Study 21143704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 20092743 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage Control Surgery (DCS)
Number of subjects: 90
Study 20092743 — intervention group
Group type: COMPARATOR
Intervention: Early Total Care (ETC)
Number of subjects: 90
Study 17284910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing glass ionomer cement
Number of subjects: 50
Study 14972420 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) at standard dose (600mg orally twice daily; SD Group; n=110)
Number of subjects: 224
Study 14972420 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at double dose (1200mg orally twice daily; DD Group; n=114)
Number of subjects: 224
Study 14972420 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) at standard dose (SD Group)
Number of subjects: 224
Study 14972420 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at double dose (DD Group)
Number of subjects: 224
Study 11856901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum (900 mg)
Number of subjects: 13
Study 11856901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum (1800 mg)
Number of subjects: 13
Study 11856901 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 mg)
Number of subjects: 13
Study 11856901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9748684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 100
Study 9748684 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 100
Study 7884329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments (high velocity, short lever adjustments of the spine)
Number of subjects: 46
Study 7884329 — intervention group
Group type: COMPARATOR
Intervention: Sham adjustment (using an Activator at a nontension setting)
Number of subjects: 46
Study 3067754 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 52
Study 3067754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29569389 — intervention group
Group type: EXPERIMENTAL
Intervention: SeR-Se-Ly (1 tablet daily for 6 months)
Number of subjects: 427
Study 29569389 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg (1 tablet daily for 6 months)
Number of subjects: 427
Study 28224232 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel (Tr14)
Number of subjects: 0
Study 26917026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov fixation
Number of subjects: 32
Study 26917026 — intervention group
Group type: EXPERIMENTAL
Intervention: LRS fixation
Number of subjects: 32
Study 26917026 — intervention group
Group type: COMPARATOR
Intervention: Rail fixators
Number of subjects: 32
Study 26917026 — intervention group
Group type: COMPARATOR
Intervention: Ring fixators
Number of subjects: 32
Study 24273971 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Pill (DXP) in addition to Metformin and Diane-35
Number of subjects: 60
Study 24273971 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Diane-35 (Control Group B)
Number of subjects: 60
Study 21948897 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-priming rTMS (4-8 Hz; 400 pulses, at 90% of motor threshold)
Number of subjects: 40
Study 21948897 — intervention group
Group type: COMPARATOR
Intervention: Sham-priming stimulation followed by low-frequency rTMS (1-Hz; 900 pulses at 110% of motor threshold)
Number of subjects: 40
Study 18296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up only
Number of subjects: 64
Study 18296979 — intervention group
Group type: COMPARATOR
Intervention: Warm-up plus static stretching
Number of subjects: 64
Study 18296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up plus dynamic stretching
Number of subjects: 64
Study 18296979 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up plus dynamic flexibility
Number of subjects: 64
Study 16530767 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day on days 1-5 of the menstrual cycle (group 1)
Number of subjects: 78
Study 16530767 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day on days 5-9 of the menstrual cycle (group 2)
Number of subjects: 78
Study 12679683 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 424
Study 12679683 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 424
Study 14676042 — intervention group
Group type: EXPERIMENTAL
Intervention: Clioquinol
Number of subjects: 36
Study 14676042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10219029 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular peripheral corneal incision (blow-off valve)
Number of subjects: 42
Study 10219029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique peripheral corneal incision (water-tight)
Number of subjects: 42
Study 10219029 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (unoperated)
Number of subjects: 42
Study 7652983 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with 20 ml of 1% lidocaine
Number of subjects: 68
Study 7652983 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anaesthesia with pethidine/diazepam
Number of subjects: 68
Study 7652983 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 68
Study 2504566 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 127
Study 2504566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 799551 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 799551 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study 31247980 — intervention group
Group type: COMPARATOR
Intervention: Conventional cocoa (CC) 15 g in 200 mL of semi-skimmed milk containing 19.80 mg of flavanols
Number of subjects: 13
Study 31247980 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (CC-PP) 25 g in 200 mL of semi-skimmed milk containing 68.25 mg of flavanols
Number of subjects: 13
Study 28842449 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent by patients themselves
Number of subjects: 1005
Study 28842449 — intervention group
Group type: COMPARATOR
Intervention: Informed consent by proxy
Number of subjects: 1005
Study 25474080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led educational telephone intervention (two scheduled calls over six weeks)
Number of subjects: 73
Study 25474080 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led educational telephone intervention
Number of subjects: 73
Study 25474080 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care including a self-management plan)
Number of subjects: 73
Study 24112817 — intervention group
Group type: COMPARATOR
Intervention: Gait training on a treadmill with placebo transcranial stimulation
Number of subjects: 0
Study 24112817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training on a treadmill with active transcranial stimulation
Number of subjects: 0
Study 24112817 — intervention group
Group type: COMPARATOR
Intervention: Mobility training with virtual reality and placebo transcranial stimulation
Number of subjects: 0
Study 24112817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility training with virtual reality and active transcranial stimulation
Number of subjects: 0
Study 21873708 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 2950
Study 21873708 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted, target INR 2.0-3.0)
Number of subjects: 2950
Study 20329617 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pricking (NP) applied mainly on bilateral points of sacral plexus and para-vertebra L1, every 5 days for 45 days.
Number of subjects: 122
Study 20329617 — intervention group
Group type: COMPARATOR
Intervention: L-dopa and ephedrine, orally 1 hour before sexual intercourse for 45 days.
Number of subjects: 122
Study 20329617 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pricking (NP)
Number of subjects: 122
Study 20329617 — intervention group
Group type: COMPARATOR
Intervention: L-dopa and ephedrine
Number of subjects: 122
Study 18332595 — intervention group
Group type: EXPERIMENTAL
Intervention: HYB exercise regimen (volitional contraction against applied electrical stimulation)
Number of subjects: 13
Study 18332595 — intervention group
Group type: COMPARATOR
Intervention: ELS Group (electrical stimulation delivered to the biceps brachii and triceps brachii with limb fixed)
Number of subjects: 13
Study 15136071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pr‐LPL mass
Number of subjects: 81
Study 11568049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (17% FIO2)
Number of subjects: 10
Study 11568049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercarbia (2.7% FICO2)
Number of subjects: 10
Study 9760627 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised form of the answer sheet for the Speech‐Sounds Perception Test (error types randomized)
Number of subjects: 40
Study 9760627 — intervention group
Group type: COMPARATOR
Intervention: Standard form of the answer sheet for the Speech‐Sounds Perception Test
Number of subjects: 40
Study 7918132 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg bid
Number of subjects: 72
Study 7918132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 2830189 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 20 mg daily for 6 weeks
Number of subjects: 16
Study 2830189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 120 mg daily for 6 weeks
Number of subjects: 16
Study 2830189 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine, 10 mg p.o. during washout phase
Number of subjects: 16
Study 2830189 — intervention group
Group type: COMPARATOR
Intervention: Enalaprilat, 5 mg i.v. during washout phase
Number of subjects: 16
Study 30963177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (child nutrition counseling plus lipid-based nutrient supplements)
Number of subjects: 1512
Study 30963177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition plus WSH (N+WSH)
Number of subjects: 1512
Study 30963177 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (WSH, Nutrition, N+WSH)
Number of subjects: 1512
Study 30963177 — intervention group
Group type: EXPERIMENTAL
Intervention: WSH
Number of subjects: 1512
Study 30963177 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1512
Study 31165374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-family agenda setting intervention
Number of subjects: 132
Study 31165374 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study 27832331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NG group)
Number of subjects: 60
Study 27832331 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube (NNG group)
Number of subjects: 60
Study 26421634 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebo treatment
Number of subjects: 35
Study 26421634 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo treatment
Number of subjects: 35
Study 26421634 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 35
Study 23491407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (n = 6)
Number of subjects: 12
Study 23491407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 20153492 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.05 μg/[kg min])
Number of subjects: 10
Study 20153492 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 10
Study 19187819 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral treatment (GCBT)
Number of subjects: 33
Study 19187819 — intervention group
Group type: COMPARATOR
Intervention: Minimum contact comparison group (MCC)
Number of subjects: 33
Study 19187819 — intervention group
Group type: EXPERIMENTAL
Intervention: GCBT
Number of subjects: 33
Study 16717173 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based health risk assessment with a prompt for the health care provider
Number of subjects: 1281
Study 16717173 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1281
Study 15251401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol (500 mg every six hours for five days)
Number of subjects: 251
Study 15251401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 11312316 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-blind subjects
Number of subjects: 0
Study 11312316 — intervention group
Group type: COMPARATOR
Intervention: Sighted subjects
Number of subjects: 0
Study 9220217 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 43
Study 9220217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7660719 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-A
Number of subjects: 25
Study 7660719 — intervention group
Group type: COMPARATOR
Intervention: Pill-combined and GnRH
Number of subjects: 25
Study 3307886 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO)
Number of subjects: 25
Study 3307886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31974572 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved infant and young child feeding (IYCF)
Number of subjects: 738
Study 31974572 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed uninfected (CHEU)
Number of subjects: 738
Study 31974572 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed children in non-IYCF arms
Number of subjects: 738
Study 29266093 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LI-RT + BFRT)
Number of subjects: 48
Study 29266093 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (HI-RT)
Number of subjects: 48
Study 29266093 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance training (LI-RT)
Number of subjects: 48